獸用皮膚病藥物市場－全球產業規模、佔有率、趨勢、機會、預測：按適應症、動物種類、給藥途徑、分銷管道、地區和競爭格局分類，2021-2031年

全球獸醫皮膚病藥物市場預計將從 2025 年的 179.8 億美元成長到 2031 年的 312.2 億美元，複合年成長率為 9.63%。

全球獸用皮膚病藥物市場涵蓋用於診斷和治療動物皮膚疾病（例如寄生蟲感染疾病、過敏性皮膚炎和自體免疫疾病）的藥品和治療製劑。該行業的主要驅動力是寵物日益人性化以及慢性皮膚病發病率的上升，這兩方面都促使寵物飼主尋求更先進的獸醫護理並制定長期用藥方案。

然而，市場擴張的一大障礙是獸醫保健成本的飆升。這一經濟壁壘限制了高品質治療的普及。治療慢性皮膚病所需的高昂費用常常給家庭預算帶來壓力，迫使一些飼主推遲甚至放棄必要的治療。澳洲動物醫學協會2025年的報告凸顯了這一經濟問題，報告指出“12%的寵物飼主在過去一年中需要獸醫費用方面的經濟援助”，這表明經濟限制會阻礙專業皮膚病藥物的廣泛應用。

市場促進因素

動物感染疾病、寄生蟲感染和過敏性皮膚病的日益增多是全球獸醫皮膚病市場的主要驅動力。隨著環境過敏原和誘發因素的擴散，異位性皮膚炎等慢性疾病的發生率不斷上升，對長期治療和管理的需求也日益強勁。保險數據也印證了這個趨勢。根據 Nationwide 保險公司 2024 年 4 月的分析，異位性皮膚炎或過敏性皮膚炎已連續 12 年成為犬類最常見的疾病，2023 年的保險索賠案例超過 41.5 萬例。這表明，迫切需要有效的配方來緩解症狀並改善動物福利。

同時，全球寵物飼養量和伴侶動物數量的成長正在擴大動物用藥品的基本客群。飼主飼養行為向「擬人化」轉變，推動了皮膚病專科醫療保健支出的增加。根據歐洲寵物食品工業聯合會（FEDIAF）於2024年6月發布的《2024年事實與數據》報告，歐洲約有1.66億戶家庭至少擁有一隻寵物，代表著一個巨大的潛在市場。寵物飼養量和支出的成長反映在強勁的企業業績上；例如，碩騰公司（Zoetis）2024年第三季皮膚病業務收入達4.49億美元，充分體現了這些因素的顯著商業性影響。

市場挑戰

獸醫保健成本的不斷上漲是全球獸醫皮膚病藥物市場成長的主要障礙。隨著診斷和長期用藥費用的增加，寵物飼主面臨經濟負擔，難以獲得高品質的皮膚病治療。這種經濟上的困難導致許多家庭推遲就醫或放棄治療慢性疾病（例如過敏性皮膚炎）所需的藥物，直接減少了處方箋數量。因此，經濟壓力抑制了需求，往往超過了人們治療那些被認為不危及生命的疾病的意願。

市場萎縮的趨勢得到了產業數據的佐證，數據顯示，經濟負擔導致消費者支出改變。美國獸醫學會（AVMA）報告稱，2024年“獸醫總支出年減4%”，這表明價格上漲正促使飼主減少對專業服務的使用。支出下降清楚地表明，成本壓力正在縮小專業皮膚病產品的基本客群，並阻礙該行業的擴張潛力。

市場趨勢

Janus激酶（JAK）抑制劑適應症的不斷擴大，正在改變該領域的競爭格局，使其從壟斷轉變為多產品治療層級。傳統的異位性皮膚炎治療僅限於單一主流製劑，但近期監管部門的核准引入了新的JAK抑制劑，使獸醫能夠根據不同的安全性特徵和給藥方案來選擇治療犬瘙癢的藥物。這種多樣性使獸醫能夠制定個人化的治療方案，從而促進了這些藥物在臨床實踐中的快速普及。例如，禮來公司（Elanco）在2025年5月報告稱，其新型皮膚病治療藥物Zenrelia已在美國約11,000家動物醫院使用，凸顯了這些口服藥物的快速商業性成功。

同時，非抗生素酶製劑的興起正成為全球抗生素抗藥性挑戰的關鍵舉措。為了減少對全身性抗生素治療皮膚感染疾病的依賴，製造商正在開發先進的局部用藥方案，例如生物黏附凝膠和藥用洗髮精，這些方案利用脂質和酵素來修復皮膚屏障並控制微生物生長。這種向多方面、非全身性治療方法的轉變正在推動專注於皮膚衛生領域的公司發展。在2025年1月的新聞稿中，Verbach宣布其伴侶動物部門經外匯調整後成長了10.7%，這一業績主要歸功於公司專業皮膚科產品線的強勁銷售。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球獸醫皮膚病市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 適應症（寄生蟲感染疾病、性行為感染、其他）
  • 動物種類（伴侶動物、家畜）
  • 給藥途徑（外用、口服、注射）
  • 分銷管道（醫院和藥房、零售、電子商務）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美獸醫皮膚病市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲獸用皮膚病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區獸用皮膚病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲獸用皮膚病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美獸用皮膚病藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球獸用皮膚病藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Sante Animale SA
• Boehringer Ingelheim International GmbH
• VETOQUINOL SA
• Bioiberica SAU
• Bimeda Inc.
• Virbac SA
• Vivaldis

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Veterinary Dermatology Drugs Market to increase from USD 17.98 Billion in 2025 to USD 31.22 Billion by 2031, with a CAGR of 9.63%. The Global Veterinary Dermatology Drugs Market comprises pharmaceutical agents and therapeutic formulations designed for diagnosing and managing animal skin disorders, such as parasitic infections, allergic dermatitis, and autoimmune conditions. This sector is primarily propelled by the growing trend of pet humanization and the increasing incidence of chronic dermatological diseases, both of which encourage pet owners to pursue advanced veterinary care and commit to long-term medication plans.

However, market expansion faces a significant obstacle in the form of rising veterinary healthcare costs, which establish financial barriers and restrict access to premium treatments. The substantial expense required to manage chronic skin conditions often strains household finances, compelling some owners to postpone or skip essential care. This affordability issue is highlighted by 'Animal Medicines Australia', which noted in '2025' that '12% of pet owners needed financial help for veterinary care in the past year', indicating that economic constraints may limit the wider adoption of specialized dermatology drugs.

Market Driver

The escalating prevalence of infectious, parasitic, and allergic skin diseases in animals acts as a major driver for the Global Veterinary Dermatology Drugs Market. As environmental allergens and triggers become more widespread, the occurrence of chronic conditions like atopic dermatitis has risen, creating a strong demand for long-term therapeutic management. Insurance data confirms this trend; according to Nationwide's April 2024 analysis, atopic or allergic dermatitis was the leading medical condition for dogs for the twelfth year in a row, with over 410,500 claims filed in 2023, demonstrating the urgent need for effective formulations to alleviate symptoms and enhance animal welfare.

Simultaneously, the global increase in pet ownership and the companion animal population is broadening the customer base for veterinary pharmaceuticals. The shift in owner behavior toward pet humanization has resulted in a higher willingness to spend on specialized healthcare for skin ailments. A June 2024 report by FEDIAF EuropeanPetFood titled 'Facts & Figures 2024' indicates that about 166 million European households own at least one pet, representing a massive addressable market. This growing ownership and expenditure are reflected in strong corporate results, such as Zoetis reporting $449 million in revenue from its dermatology franchise in the third quarter of 2024, illustrating the substantial commercial impact of these factors.

Market Challenge

Rising veterinary healthcare costs pose a significant barrier to the growth of the Global Veterinary Dermatology Drugs Market. As the prices for diagnostics and long-term pharmaceutical management increase, pet owners encounter financial hurdles that limit their access to premium dermatological therapies. This affordability crisis leads many households to delay professional consultations or forgo necessary medications for chronic issues like allergic dermatitis, directly reducing prescription volumes. Consequently, demand is suppressed as economic pressures override the desire to treat conditions that are often perceived as non-life-threatening.

This market contraction is supported by industry data indicating a shift in consumer spending due to economic strain. The 'American Veterinary Medical Association' reported in '2024' that 'overall veterinary spending decreased by 4% compared to the previous year', suggesting that higher prices are forcing owners to cut back on professional services. This decline in expenditure demonstrates how cost pressures are effectively shrinking the customer base for specialized dermatology drugs, thereby hindering the sector's potential for wider expansion.

Market Trends

The expansion of Janus Kinase (JAK) inhibitor applications is transforming the sector's competitive landscape from a monopoly into a multi-product therapeutic class. While earlier treatments for atopic dermatitis were restricted to a single dominant formulation, recent regulatory approvals have introduced new JAK inhibitors that provide veterinarians with alternative safety profiles and dosing regimens for managing canine pruritus. This variety enables practitioners to customize treatment plans, leading to rapid adoption in general practice; for example, Elanco reported in May 2025 that its new dermatology treatment, Zenrelia, had been adopted by roughly 11,000 U.S. veterinary clinics, highlighting the swift commercial success of these oral therapeutics.

In parallel, the rise of non-antibiotic enzymatic topicals is becoming a key response to the global issue of antimicrobial resistance. To decrease reliance on systemic antibiotics for skin infections, manufacturers are developing advanced topical solutions, such as bio-adhesive gels and medicated shampoos, which use lipids and enzymes to restore the skin barrier and control microbial growth. This shift toward multimodal, non-systemic management is driving growth for companies specializing in dermatological hygiene; Virbac's January 2025 press release noted a 10.7% growth in its companion animal division at constant exchange rates, a performance largely attributed to the strong sales of its specialized dermatology line.

Key Market Players

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Sante Animale S.A.
• Boehringer Ingelheim International GmbH
• VETOQUINOL S.A.
• Bioiberica S.A.U.
• Bimeda Inc.
• Virbac S.A.
• Vivaldis

Report Scope

In this report, the Global Veterinary Dermatology Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Dermatology Drugs Market, By Indication

• Parasitic Infections
• Allergic Infections
• Others

Veterinary Dermatology Drugs Market, By Animal Type

• Companion Animals
• Livestock Animals

Veterinary Dermatology Drugs Market, By Route of Administration

• Topical
• Oral
• Injectable

Veterinary Dermatology Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Retail
• E-commerce

Veterinary Dermatology Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Dermatology Drugs Market.

Available Customizations:

Global Veterinary Dermatology Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Dermatology Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Parasitic Infections, Allergic Infections, Others)
  • 5.2.2. By Animal Type (Companion Animals, Livestock Animals)
  • 5.2.3. By Route of Administration (Topical, Oral, Injectable)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail, E-commerce)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Veterinary Dermatology Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Animal Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Veterinary Dermatology Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Animal Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Veterinary Dermatology Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Animal Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Veterinary Dermatology Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Animal Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Veterinary Dermatology Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Animal Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Veterinary Dermatology Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Animal Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Veterinary Dermatology Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Animal Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Veterinary Dermatology Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Animal Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Veterinary Dermatology Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Animal Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Veterinary Dermatology Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Animal Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Veterinary Dermatology Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Animal Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Veterinary Dermatology Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Animal Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Veterinary Dermatology Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Animal Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Veterinary Dermatology Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Animal Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Veterinary Dermatology Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Animal Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Veterinary Dermatology Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Animal Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Veterinary Dermatology Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Animal Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Veterinary Dermatology Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Animal Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Veterinary Dermatology Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Animal Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Veterinary Dermatology Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Animal Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Veterinary Dermatology Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Animal Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Veterinary Dermatology Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Animal Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Veterinary Dermatology Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Animal Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Veterinary Dermatology Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Animal Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Veterinary Dermatology Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. Elanco Animal Health Inc.
• 15.4. Ceva Sante Animale S.A.
• 15.5. Boehringer Ingelheim International GmbH
• 15.6. VETOQUINOL S.A.
• 15.7. Bioiberica S.A.U.
• 15.8. Bimeda Inc.
• 15.9. Virbac S.A.
• 15.10. Vivaldis

16. Strategic Recommendations

17. About Us & Disclaimer